This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and genetherapies. Many novel therapies have been successfully developed through such partnerships. Case Study: From Technology Agreement to co-development and co-commercialisation partnership.
Last month we saw some movement in the pharma world, but also in some of the orbiting worlds of agencies, consultancies, and pharma investors. In addition, two team members are taking on new roles at the company, with Glen Webster named EVP of global operations and Jennifer White named global head of growth. New CEO joins UBC.
In 2024, pharmacompanies and emerging biotechs will improve candidate safety profiles and reduce off-target effects by exploiting predictive intelligence unlocked by AI,” she predicts. CRISPR GeneEditing Therapeutics CRISPR/Cas-9 technology makes lists like this almost every year, and for good reason.
Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. Maybe in 50 years’ time we’ll be using geneediting to lower cholesterol, but it won’t replace statins in anyone but those with life threatening mutations for a long time”.
Several biotech companies and researchers are now exploring medical devices and genetherapies to address not just common forms of epilepsy, but also rare conditions such as Dravet Syndrome. To tackle this, companies have developed different ways to focus on the gene.
For example, on the pharma and biotech side, there has been growing demand for new drugs and biologics, from new classes of dual-action diabetes and weight loss drugs like Ozempic and Mounjaro to life-saving genetherapies. 1. Cell and GeneTherapies.
Enzymatic DNA production company Touchlight have augmented its DNA production capabilities with a newly announced expansion to its London facilities. Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA genetherapies and vaccines.
While these therapies span all stages of clinical development, they are particularly concentrated in earlier phases, indicating strong future growth. RNA-based therapies hold the potential to offer new treatment options for diseases with limited or inadequate therapeutic alternatives. billion in 2021, is projected to reach $42.56
Pediatric cancer care has traditionally relied on chemotherapy, radiation and surgery, but emerging therapies are expanding possibilities. While obstacles such as delivery barriers, immune responses and regulatory approvals remain, clinical trials are refining these approaches, bringing hope for more effective and less toxic therapies.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content